Adimmune Corporation (4142.TW)
TWD 18.5
(2.78%)
TWD 18.5
(2.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -512.42 Million TWD | -126.75% |
| 2022 | 443.11 Million TWD | 73.85% |
| 2021 | 254.88 Million TWD | -82.39% |
| 2020 | 1.44 Billion TWD | 4442.51% |
| 2019 | -33.32 Million TWD | 90.83% |
| 2018 | -372.11 Million TWD | 18.49% |
| 2017 | -445.84 Million TWD | -47.49% |
| 2016 | -302.29 Million TWD | 24.43% |
| 2015 | -400.02 Million TWD | -25.4% |
| 2014 | -318.98 Million TWD | 2.25% |
| 2013 | -326.33 Million TWD | 10.92% |
| 2012 | -366.55 Million TWD | -9.91% |
| 2011 | -333.3 Million TWD | -174.02% |
| 2010 | 450.25 Million TWD | -47.49% |
| 2009 | 861.37 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -139.12 Million TWD | 66.0% |
| 2024 Q2 | -240.36 Million TWD | -83.06% |
| 2023 Q4 | -129.1 Million TWD | -131.91% |
| 2023 FY | - TWD | -126.75% |
| 2023 Q3 | 404.54 Million TWD | 319.14% |
| 2023 Q1 | -209.37 Million TWD | -313.71% |
| 2023 Q2 | -184.6 Million TWD | 11.83% |
| 2022 FY | - TWD | 73.85% |
| 2022 Q1 | -181.45 Million TWD | -152.81% |
| 2022 Q2 | 47.66 Million TWD | 126.27% |
| 2022 Q4 | 97.97 Million TWD | -79.54% |
| 2022 Q3 | 478.92 Million TWD | 904.76% |
| 2021 FY | - TWD | -82.39% |
| 2021 Q4 | 343.59 Million TWD | 57.15% |
| 2021 Q1 | -202.72 Million TWD | -115.78% |
| 2021 Q2 | -104.61 Million TWD | 48.4% |
| 2021 Q3 | 218.63 Million TWD | 308.99% |
| 2020 Q3 | 211.08 Million TWD | 329.86% |
| 2020 Q2 | -91.83 Million TWD | -312.64% |
| 2020 Q1 | 43.18 Million TWD | 23.38% |
| 2020 Q4 | 1.28 Billion TWD | 508.55% |
| 2020 FY | - TWD | 4442.51% |
| 2019 Q3 | 172.27 Million TWD | 260.71% |
| 2019 FY | - TWD | 90.83% |
| 2019 Q1 | -133.4 Million TWD | 53.42% |
| 2019 Q2 | -107.19 Million TWD | 19.64% |
| 2019 Q4 | 35 Million TWD | -79.68% |
| 2018 Q3 | 38.54 Million TWD | 463.03% |
| 2018 FY | - TWD | 18.49% |
| 2018 Q4 | -286.36 Million TWD | -842.97% |
| 2018 Q2 | -10.61 Million TWD | 89.88% |
| 2018 Q1 | -104.95 Million TWD | 54.18% |
| 2017 Q2 | -68.29 Million TWD | 41.09% |
| 2017 FY | - TWD | -47.49% |
| 2017 Q3 | -32.57 Million TWD | 52.31% |
| 2017 Q1 | -115.93 Million TWD | 12.18% |
| 2017 Q4 | -229.03 Million TWD | -603.15% |
| 2016 Q3 | -51.73 Million TWD | -10.67% |
| 2016 FY | - TWD | 24.43% |
| 2016 Q1 | -71.79 Million TWD | 65.19% |
| 2016 Q2 | -46.74 Million TWD | 34.89% |
| 2016 Q4 | -132 Million TWD | -155.15% |
| 2015 Q4 | -206.25 Million TWD | -75.36% |
| 2015 FY | - TWD | -25.4% |
| 2015 Q3 | -117.61 Million TWD | -4784.26% |
| 2015 Q1 | -73.75 Million TWD | 50.74% |
| 2015 Q2 | -2.4 Million TWD | 96.73% |
| 2014 Q3 | -126.47 Million TWD | -651.63% |
| 2014 Q4 | -149.72 Million TWD | -18.39% |
| 2014 Q1 | -65.71 Million TWD | 59.5% |
| 2014 FY | - TWD | 2.25% |
| 2014 Q2 | 22.92 Million TWD | 134.89% |
| 2013 Q3 | -23.82 Million TWD | 49.02% |
| 2013 Q1 | -93.5 Million TWD | 7.7% |
| 2013 FY | - TWD | 10.92% |
| 2013 Q4 | -162.25 Million TWD | -580.93% |
| 2013 Q2 | -46.74 Million TWD | 50.01% |
| 2012 Q2 | -87.05 Million TWD | 6.74% |
| 2012 Q4 | -101.3 Million TWD | -17.23% |
| 2012 Q3 | -86.41 Million TWD | 0.73% |
| 2012 Q1 | -93.34 Million TWD | 30.28% |
| 2012 FY | - TWD | -9.91% |
| 2011 Q3 | -64.31 Million TWD | 38.12% |
| 2011 FY | - TWD | -174.02% |
| 2011 Q4 | -133.88 Million TWD | -108.19% |
| 2011 Q2 | -103.91 Million TWD | -233.18% |
| 2011 Q1 | -31.19 Million TWD | 46.54% |
| 2010 Q3 | -53.49 Million TWD | 0.0% |
| 2010 FY | - TWD | -47.49% |
| 2010 Q4 | -58.34 Million TWD | -9.08% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Biotechnology Corp. | 221.06 Million TWD | 331.805% |
| Sinphar Pharmaceutical Co.,Ltd. | 582.94 Million TWD | 187.904% |
| Panion & Bf Biotech Inc. | 327.21 Million TWD | 256.601% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 473.81 Million TWD | 208.15% |
| GenMont Biotech Incorporation | 71.76 Million TWD | 814.006% |
| Abnova (Taiwan) Corporation | 81.2 Million TWD | 730.999% |
| Tanvex BioPharma, Inc. | -1.75 Billion TWD | 70.793% |
| Polaris Group | -1.38 Billion TWD | 63.121% |
| Energenesis Biomedical CO.,LTD. | -244.57 Million TWD | -109.516% |
| UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | -810.562% |
| PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | -45.091% |